Author Correction: A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD

1. These authors contributed equally: Shuo Liu, Zijing Jia, Jianhui Nie, and Ziteng Liang.

Authors and Affiliations

1. Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China

   Shuo Liu, Jianhui Nie, Ziteng Liang, Li Zhang, Youchun Wang & Weijin Huang

2. CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

   Zijing Jia, Lei Wang & Xiangxi Wang

3. Graduate School of Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

   Ziteng Liang & Youchun Wang

4. Beijing Biocytogen Co., Ltd, Beijing, China

   Jingshu Xie

Corresponding authors

Correspondence to Xiangxi Wang, Youchun Wang or Weijin Huang.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions